Procollagen type III N-terminal propeptide
1 paper2 findings
- Humans1
Effects
2Clinical model discrimination of DXA-defined sarcopenia
no changein humans1
1 study
Clinical model discrimination of DXA-defined sarcopenia
no changein humans1
Procollagen type III N-terminal propeptide has no effect on clinical model discrimination of DXA-defined sarcopenia in humans (ΔAUC = 0.007; no clinically significant improvement).
“When incorporated into the clinical model, P3NP did not yield a clinically significant improvement (ΔAUC = 0.007).”
Humanstype 2 diabetes mellitus; addition to standard clinical predictorsfemalesn = 99
Archives of endocrinology and metabolism15 Oct 2026
DXA-defined sarcopenia
no changein humans1
1 study
DXA-defined sarcopenia
no changein humans1
Procollagen type III N-terminal propeptide has no effect on DXA-defined sarcopenia in humans.
“was not independently associated with DXA-defined sarcopenia (odds ratio per 1-standard deviation, p > 0.05).”
Humanstype 2 diabetes mellitus; adjusted clinical modelfemalesn = 99
Archives of endocrinology and metabolism15 Oct 2026
Latest
1 in 12 monthsArchives of Endocrinology and Metabolism
Evaluating procollagen type III N-terminal propeptide (P3NP) as a biomarker of sarcopenia in women with type 2 diabetes: a cross-sectional study
Cross-sectional study of 99 peopleSarcopenia